160 related articles for article (PubMed ID: 12214468)
1. [A new regimen for TS-1 therapy designed to minimize adverse reactions by introducing a one-week interval after each two-week dosing session].
Kimura Y; Kikkawa N; Iijima S; Kato T; Naoi Y; Hayashi T; Tanigawa T; Yamamoto H; Kurokawa E
Gan To Kagaku Ryoho; 2002 Aug; 29(8):1403-9. PubMed ID: 12214468
[TBL] [Abstract][Full Text] [Related]
2. A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice.
Kimura Y; Kikkawa N; Iijima S; Kato T; Naoi Y; Hayashi T; Tanigawa T; Yamamoto H; Kurokawa E
Gastric Cancer; 2003; 6 Suppl 1():34-9. PubMed ID: 12775018
[TBL] [Abstract][Full Text] [Related]
3. Alternate-day oral therapy with TS-1 for advanced gastric cancer.
Arai W; Hosoya Y; Hyodo M; Yokoyama T; Hirashima Y; Yasuda Y; Nagai H; Shirasaka T
Int J Clin Oncol; 2004 Jun; 9(3):143-8. PubMed ID: 15221596
[TBL] [Abstract][Full Text] [Related]
4. [Adverse reactions to TS-1 for outpatients with recurrent head and neck cancer].
Nishino H; Shinozaki T; Ishikawa K; Tanaka H; Ichimura K
Gan To Kagaku Ryoho; 2002 Nov; 29(11):2019-23. PubMed ID: 12465408
[TBL] [Abstract][Full Text] [Related]
5. [Adjuvant chemotherapy with TS-1 for head and neck cancer--side effect of two-week application followed by one-week rest regimen].
Itoi A; Takashima M; Ishimasa H; Murata H; Tomoda K
Gan To Kagaku Ryoho; 2006 May; 33(5):617-20. PubMed ID: 16685159
[TBL] [Abstract][Full Text] [Related]
6. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
[TBL] [Abstract][Full Text] [Related]
7. [Clinical results of single therapy with TS-1 for advanced/recurrent gastric cancer].
Ohshima T; Yamada R; Hatori S; Kunisaki C; Makino T; Yamazaki Y; Suda T; Rino Y; Takanashi Y; Imada T
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1105-10. PubMed ID: 16912529
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of pre-operative administration of TS-1 in patients with advanced gastric or colorectal cancer--estimation of pathological effectiveness for postoperative adjuvant chemotherapy with TS-1].
Nakano K; Koizumi H; Okugawa K; Nakamura K; Osaka Y; Tsuchiya K; Sako H; Tanabe S; Nakane Y
Gan To Kagaku Ryoho; 2005 Mar; 32(3):329-33. PubMed ID: 15791815
[TBL] [Abstract][Full Text] [Related]
9. [A surgical case of recurrent gastric cancer successfully treated by TS-1 plus low-dose consecutive administration of CDDP following TS-1 monotherapy].
Yamada Y; Kubo N; Ako E; Sawai Y
Gan To Kagaku Ryoho; 2002 Jan; 29(1):131-4. PubMed ID: 11816470
[TBL] [Abstract][Full Text] [Related]
10. [Examination of the feasibility of TS-1 for postoperative advance stomach cancer patients].
Hara A; Tokuhara T; Takahashi Y; Izumi N; Iwamoto S; Satake K
Gan To Kagaku Ryoho; 2004 Apr; 31(4):601-4. PubMed ID: 15114708
[TBL] [Abstract][Full Text] [Related]
11. [Examination of s-1 therapy for adjuvant chemotherapy in patients with advanced gastric cancer].
Matsui K; Nashimoto A; Yabusaki H; Nakagawa S; Nomura T; Takii Y; Tsuchiya Y; Tanaka O
Gan To Kagaku Ryoho; 2009 Jun; 36(6):953-7. PubMed ID: 19542714
[TBL] [Abstract][Full Text] [Related]
12. [Pilot study of TS-1 combined with lentinan in patients with unresectable or recurrent advanced gastric cancer].
Nimura H; Mitsumori N; Tsukagoshi S; Nakajima M; Atomi Y; Suzuki S; Kusano M; Yoshiyuki T; Tokunaga A
Gan To Kagaku Ryoho; 2003 Sep; 30(9):1289-96. PubMed ID: 14518408
[TBL] [Abstract][Full Text] [Related]
13. [Clinical study of TS-1 therapy for inoperable and recurrent gastric cancer].
Moriwaki T; Hyodo I; Nishina T; Kajiwara T; Tsuzuki T; Hirao K; Nakauchi M; Nasu J; Hirasaki S; Endo H; Masumoto T; Tanimizu M; Kubo Y; Kurita A
Gan To Kagaku Ryoho; 2003 Apr; 30(4):489-94. PubMed ID: 12722679
[TBL] [Abstract][Full Text] [Related]
14. [A phase I study of combination chemotherapy using TS-1 and pirarubicin (THP) for advanced gastric cancer].
Yamamura Y; Kodera Y; Tanemura H; Oshita H; Miyashita K; Fujimura T;
Gan To Kagaku Ryoho; 2004 Mar; 31(3):361-5. PubMed ID: 15045941
[TBL] [Abstract][Full Text] [Related]
15. [Gastric cancer with multiple liver metastases, which responded significantly to oral administration of TS-1 following intravenous FMP therapy under hospitalization].
Tasaka K; Okada Y; Tomofuji Y; Chinzei T
Gan To Kagaku Ryoho; 2002 Sep; 29(9):1631-5. PubMed ID: 12355951
[TBL] [Abstract][Full Text] [Related]
16. [A clinical results of TS-1 in advanced and recurrent gastric cancer in our hospital].
Abe S; Kojima M; Tamura H; Kurihara H; Kitago M; Kobayashi T; Nakamura T; Ogihara T
Gan To Kagaku Ryoho; 2003 Jul; 30(7):963-70. PubMed ID: 12894711
[TBL] [Abstract][Full Text] [Related]
17. [Clinical evaluation, including QOL of TS-1 for patients with locally advanced or recurrent gastric cancer at ambulatory setting].
Oeda M; Hirabayashi N; Takiyama W; Nagamine I; Ohara M; Oshita A; Satou Y; Saeki S; Kirihara Y; Mukaida H; Hisamatu K
Gan To Kagaku Ryoho; 2003 Oct; 30(10):1453-8. PubMed ID: 14584277
[TBL] [Abstract][Full Text] [Related]
18. [Successful treatment of gastric cancer accompanied by multiple liver metastases with TS-1 followed by curative gastrectomy affiliation].
Inoue S; Umekita N; Kitamura M
Gan To Kagaku Ryoho; 2002 Jun; 29(6):939-42. PubMed ID: 12090048
[TBL] [Abstract][Full Text] [Related]
19. Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination.
Osugi H; Takada N; Takemura M; Kaseno S; Lee S; Ueno M; Tanaka Y; Fukuhara K; Fujiwara Y; Kinoshita H
Oncol Rep; 2002; 9(4):811-5. PubMed ID: 12066214
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and safety of novel oral fluoropyrimidine anticancer drug, TS-1 for advanced and recurrent gastric cancer patients].
Arai K; Iwasaki Y; Kimura Y; Takahashi K; Yamaguchi T; Honma S; Takahashi T
Gan To Kagaku Ryoho; 2003 Sep; 30(9):1297-301. PubMed ID: 14518409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
